1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,010 | 1,150 | 21.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | GENENTA SCIENCE SPA: Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm | 503 | GlobeNewswire (Europe) | MILAN and NAPLES, Italy, July 23, 2026 (GLOBE NEWSWIRE) -- Sòphia High Tech S.r.l. (Sòphia HT), an Italian aerospace and defense company manufacturing critical parts for Europe's space and defense... ► Artikel lesen | |
| 22.07. | GENENTA SCIENCE SPA: Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results | 493 | GlobeNewswire (Europe) | Fiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of production increased 34.7% to €8.47 millionEBITDA grew 68.1% to €1.61 million, expanding the EBITDA margin by approximately... ► Artikel lesen | |
| 14.07. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.07. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.06. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.06. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| GENENTA SCIENCE Aktie jetzt für 0€ handeln | |||||
| 19.05. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.04. | Genenta: €6 Million Deal For Sophia High Tech Marks Entry Into Aerospace And Defense With Majority Stake Path | 2 | pulse2.com | ||
| 23.04. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.04. | Genenta to buy majority stake in aerospace parts maker for €6M | 4 | Seeking Alpha | ||
| 23.04. | GENENTA SCIENCE SPA: Genenta signs Definitive Agreements with Sophia High Tech | 498 | GlobeNewswire (Europe) | MILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and... ► Artikel lesen | |
| 14.04. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.03. | GENENTA SCIENCE SPA: Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs | 867 | GlobeNewswire (Europe) | MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian... ► Artikel lesen | |
| 24.03. | GENENTA SCIENCE SPA: Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini | 394 | GlobeNewswire (Europe) | MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian... ► Artikel lesen | |
| 13.03. | GENENTA SCIENCE SPA: Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University | 588 | GlobeNewswire (Europe) | MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 28.02. | Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business | 4 | Insider Monkey | ||
| 27.02. | GENENTA SCIENCE SPA: Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform | 666 | GlobeNewswire (Europe) | MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 27.01. | GENENTA SCIENCE SPA: Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator | 534 | GlobeNewswire (Europe) | Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial... ► Artikel lesen | |
| 19.12.25 | GENENTA SCIENCE SPA: Genenta Science Provides Update on CEO Ownership | 399 | GlobeNewswire (Europe) | MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors... ► Artikel lesen | |
| 24.11.25 | GENENTA SCIENCE SPA: Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial | 425 | GlobeNewswire (Europe) | MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,356 | 0,00 % | Evotec-Aktie: Hier entsteht jetzt Multibagger-Potenzial | Die Evotec-Aktie steht erneut unter Druck. Im Xetra-Handel fällt das Papier heute zeitweise um gut zwei Prozent auf rund 3,36 Euro und damit ein neues Langzeittief. Der Titel steht weiterhin im Schatten... ► Artikel lesen | |
| BB BIOTECH | 59,70 | +0,34 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MODERNA | 123,92 | -0,26 % | Moderna Aktie: Was für ein Wahnsinn bei Moderna! Kippt aber jetzt die Stimmung?! | © Foto: Finanznachrichten (Symbolbild wurde mit KI erstellt)Erst ein Kurssprung wie ihn kaum eine Aktie je erlebt hat, dann der schnelle Absturz, aber kommt jetzt wieder eine Erholung? Moderna sorgt... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 51,16 | +0,45 % | CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? | ||
| NANOREPRO | 1,910 | +1,33 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
18.08.2026 / 07:30... ► Artikel lesen | |
| AAP IMPLANTATE | 1,520 | +3,40 % | EQS-News: aap Implantate AG: aap verbessert Profitabilität im ersten Halbjahr 2026 und startet mit Rekordauftragseingang in die zweite Jahreshälfte | EQS-News: aap Implantate AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
aap verbessert Profitabilität im ersten Halbjahr 2026 und startet mit Rekordauftragseingang in... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,029 | +1,38 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,759 | -1,95 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,020 | +0,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 62,20 | -0,08 % | AKTIONÄR-Tipp Personalis: Der Schlüssel für Moderna und Co - bekommt Tempus AI kalte Füße? | Mit positiven Phase-3-Studiendaten eines personalisierten mRNA-Krebsimpfstoffs bei Melanomen haben Moderna und der Forschungspartner Merck & Co in dieser Woche für Schlagzeilen gesorgt. Doch damit das... ► Artikel lesen | |
| EDITAS MEDICINE | 2,600 | -2,26 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 58,02 | +1,58 % | BioMarin Pharmaceutical Inc.: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline | BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones
Alesta to spin out all non-ALE1 assets... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,602 | +0,25 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| EVONEXT | 2,580 | +1,57 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG
17-Aug-2026 / 17:50 CET/CEST
Release of... ► Artikel lesen | |
| IBIO | 1,190 | -3,17 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen |
GENENTA SCIENCE SPA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,07 % bei einem Aktienkurs von 0,945 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENENTA SCIENCE SPA ADR finden Sie auf Wallstreet Online.